ruxolitinib cream
Selected indexed studies
- Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. (N Engl J Med, 2022) [PMID:36260792]
- Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo. (Drugs, 2024) [PMID:38625661]
- Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. (Lancet, 2020) [PMID:32653055]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo. (2024) pubmed
- Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. (2022) pubmed
- Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. (2020) pubmed
- Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis. (2023) pubmed
- Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies. (2021) pubmed
- Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with atopic dermatitis: Results from TRuE-AD3, a phase 3, randomized double-blind study. (2025) pubmed
- Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream. (2020) pubmed
- Ruxolitinib cream for the short-term treatment of mild-moderate atopic dermatitis. (2023) pubmed
- Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies. (2024) pubmed
- Ruxolitinib Cream Monotherapy Improved Symptoms and Quality of Life in Adults and Adolescents with Mild-to-Moderate Atopic Dermatitis: Patient-Reported Outcomes from Two Phase III Studies. (2025) pubmed